Retrotope’s drug platform, deuterium stabilized PUFAs, aims to preserve and restore mitochondrial health in degenerative diseases including Parkinson’s, Alzheimer’s, and diabetic retinopathy, among others. The unique mechanism of this new category of drugs prevents cellular damage and recovers cellular function damaged by lipid peroxidation.